The EGM is over, and it was revealed that no trials have reported anything of note. Ropren sales are many months away, leading some analysts to suggest that SLA is "dead money." I am generally more optimistic, but I can't see any positive catalysts on the horizon. Anyway, with the directors the only ones buying, there is really little possibility of rebalancing the portfolio. Holders have no choice but to be patient, and hope for greater liquidity.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.010(5.26%) |
Mkt cap ! $10.66M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.0¢ | $9.06K | 49.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 31000 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 7422 | 1 |
View Market Depth
| Last trade - 14.41pm 19/09/2025 (20 minute delay) ? |
| SLA (ASX) Chart |